|
SPG20 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.78423942287509E-12 |
| Normal-vs-Stage2 |
1.59799999899235E-08 |
| Normal-vs-Stage3 |
2.22044604925031E-16 |
| Normal-vs-Stage4 |
1.64468438867971E-12 |
| Stage1-vs-Stage2 |
4.926600E-01 |
| Stage1-vs-Stage3 |
4.639600E-01 |
| Stage1-vs-Stage4 |
8.525800E-02 |
| Stage2-vs-Stage3 |
2.629200E-01 |
| Stage2-vs-Stage4 |
7.706500E-02 |
| Stage3-vs-Stage4 |
3.055000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.64368518795754E-12 |
| Normal-vs-AfricanAmerican |
2.07749999999729E-05 |
| Normal-vs-Asian |
1.25940369244404E-11 |
| Caucasian-vs-AfricanAmerican |
6.341600E-02 |
| Caucasian-vs-Asian |
6.351800E-01 |
| AfricanAmerican-vs-Asian |
1.819980E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.567800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.31228361510694E-13 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62525548574877E-12 |
| Normal-vs-Age(81-100Yrs) |
4.44499999999737E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.810800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.244200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.828800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.833000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.768600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.216000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.423900E-02 |
| Classical-VS-Follicular |
4.158400E-01 |
| Classical-VS-Other |
5.317600E-01 |
| Classical-VS-Normal |
2.81374923361E-12 |
| Tall-VS-Follicular |
3.072100E-02 |
| Tall-VS-Other |
7.731600E-01 |
| Tall-VS-Normal |
3.75921516138078E-13 |
| Follicular-VS-Other |
4.677600E-01 |
| Follicular-VS-Normal |
3.93790000607908E-10 |
| Other-VS-Normal |
2.796300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.50910403565285E-14 |
| N0-vs-N1 |
1.525420E-01 |
|
|
